227 related articles for article (PubMed ID: 21822144)
1. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
Moore KT; Plotnikov AN; Thyssen A; Vaccaro N; Ariyawansa J; Burton PB
J Cardiovasc Pharmacol; 2011 Dec; 58(6):581-8. PubMed ID: 21822144
[TBL] [Abstract][Full Text] [Related]
2. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
3. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
Kubitza D; Becka M; Zuehlsdorf M; Mueck W
J Clin Pharmacol; 2007 Feb; 47(2):218-26. PubMed ID: 17244773
[TBL] [Abstract][Full Text] [Related]
4. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.
Kubitza D; Becka M; Roth A; Mueck W
J Clin Pharmacol; 2013 Mar; 53(3):249-55. PubMed ID: 23381840
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
6. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
7. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
Kubitza D; Becka M; Mueck W; Zuehlsdorf M
J Clin Pharmacol; 2006 Sep; 46(9):981-90. PubMed ID: 16920892
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.
Kubitza D; Becka M; Mueck W; Zuehlsdorf M
Br J Clin Pharmacol; 2007 Apr; 63(4):469-76. PubMed ID: 17100983
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
Kreutz R
Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
[TBL] [Abstract][Full Text] [Related]
13. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
[TBL] [Abstract][Full Text] [Related]
14. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Andersson T; Nagy P; Niazi M; Nylander S; Galbraith H; Ranjan S; Wallentin L
Am J Cardiovasc Drugs; 2014 Jun; 14(3):217-27. PubMed ID: 24677117
[TBL] [Abstract][Full Text] [Related]
15. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
Kubitza D; Becka M; Zuehlsdorf M; Mueck W
J Clin Pharmacol; 2006 May; 46(5):549-58. PubMed ID: 16638738
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Abrams PJ; Emerson CR
Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
[TBL] [Abstract][Full Text] [Related]
17. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
Fontes-Carvalho R; Albuquerque A; Araújo C; Pimentel-Nunes P; Ribeiro VG
Eur J Gastroenterol Hepatol; 2011 May; 23(5):396-404. PubMed ID: 21464720
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
Gheorghiade M; Thyssen A; Zolynas R; Nadar VK; Greenberg BH; Mehra M; Sun X; Tian H; Plotnikov AN; Burton P
J Heart Lung Transplant; 2011 Feb; 30(2):218-26. PubMed ID: 20947383
[TBL] [Abstract][Full Text] [Related]
19. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
20. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
Kubitza D; Roth A; Becka M; Alatrach A; Halabi A; Hinrichsen H; Mueck W
Br J Clin Pharmacol; 2013 Jul; 76(1):89-98. PubMed ID: 23294275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]